News
ARQT
8.59
-1.83%
-0.16
New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) analysts have upgraded their revenue forecasts for the company. The consensus is for revenues of US$117m in 2024. This is a 97% increase on the previous year. The company is expected to grow faster than the wider industry in the years to come. The analysts have also upgraded their estimates for Arcutis's losses this year.
Simply Wall St · 15h ago
Weekly Report: what happened at ARQT last week (0415-0419)?
Weekly Report · 3d ago
Analysts Conflicted on These Healthcare Names: Terns Pharmaceuticals (TERN), Abbott Labs (ABT) and Arcutis Biotherapeutics (ARQT)
TipRanks · 3d ago
Weekly Report: what happened at ARQT last week (0408-0412)?
Weekly Report · 04/15 09:14
Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts
5 analysts have published ratings on Arcutis Biotherapeutics in the last three months. The company is a medical dermatology company developing treatments for patients with immune-mediated dermatological diseases and conditions. The average 12-month price target of $15.2 is an increase of 60.0% from the previous average of $9.50. Ar cutis biotherapeutic has an average revenue growth rate of 356.81% over the past year.
Benzinga · 04/12 12:00
Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT)
TipRanks · 04/12 10:40
Arcutis Biotherapeutics Welcomes New CFO David Topper
TipRanks · 04/10 20:33
Arcutis Biotherapeutics appoints CFO
Arcutis Biotherapeutics appoints David Topper as CFO effective April 10. Topper replaces interim CFO John Smither. Arcutis is a biopharmaceutical company focused on treatments for dermatological diseases. The company's stock is up 2.7% in the last week.
Seeking Alpha · 04/10 12:16
Arcutis Biotherapeutics Names David Topper as Finance Chief
Arcutis Biotherapeutics names David Topper to succeed John Smither as chief financial officer. Smither rejoined the company in August as interim CFO. Topper joins Arcutis from clinical stage pharmaceutical company Inmagene Biopharmaceuticals.
Dow Jones · 04/10 12:14
*Arcutis Biotherapeutics: Smither Will Remain to End of April to Ensure Smooth Transition >ARQT
Dow Jones · 04/10 12:02
*Arcutis Biotherapeutics: Topper Replaces Interim CFO John Smither >ARQT
Dow Jones · 04/10 12:01
ARCUTIS BIOTHERAPEUTICS INC - DAVID TOPPER IS REPLACING JOHN SMITHER
Reuters · 04/10 12:00
Press Release: Arcutis Appoints David Topper as Chief Financial Officer
Arcutis Appoints David Topper as Chief Financial Officer Industry veteran with over 40 years of experience in finance, investment management, and investment banking. Topper joins Arcutis from Inmagene Biopharmaceuticals. He is replacing John Smither as interim CFO effective April 10, 2024. Ar cutis is a commercial-stage company focused on developing meaningful innovations in immuno-dermatology.
Dow Jones · 04/10 12:00
*Arcutis Biotherapeutics Appoints David Topper as Chief Fincl Officer >ARQT
Dow Jones · 04/10 12:00
Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Arcutis Biotherapeutics (ARQT)
TipRanks · 04/10 06:30
Buy Rating on Arcutis Biotherapeutics Bolstered by Projected Q1 Sales Beat and 2024 Upside Potential
TipRanks · 04/10 06:21
Weekly Report: what happened at ARQT last week (0401-0405)?
Weekly Report · 04/08 09:16
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics, Inc. Grants an aggregate of 58,500 restricted stock units of Arcutis’ common stock to four newly hired employees. The company is a commercial-stage biopharmaceutical company focused on developing innovations in immuno-dermatology.
Barchart · 04/05 15:00
SOL-GEL’S COLLABORATION PARTNER FIRST-TO-FILE ANDA DRUG PRODUCT GENERIC TO ZORYVE® CREAM
Reuters · 04/01 11:00
Weekly Report: what happened at ARQT last week (0325-0329)?
Weekly Report · 04/01 09:15
More
Webull provides a variety of real-time ARQT stock news. You can receive the latest news about Arcutis Biotherapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. ARQ-255 is developed for alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo. ARQ-255 is developed for the treatment of alopecia areata.